Mr. Robert Thast reports

IZOTROPIC CEO RESIGNS

Effective May 31, 2023, Dr. John McGraw has resigned as chief executive officer of Izotropic Corp. for personal reasons and has stepped down from the company's board of directors. Dr. McGraw will remain an adviser to the company and will consult on future projects.

The company thanks Dr. McGraw for his service and management contributions over the past three years.

Effective June 1, 2023, Izotropic founder, chairman and former chief executive officer Robert Thast assumed the role of interim CEO and will work closely with the company's directors regarding business decisions and operational matters until a new CEO is in place.

Izotropic has initiated its search for a new CEO with broad public-company and financing expertise and global experience in health care imaging and marketing.

About Izotropic Corp.

Izotropic is the only publicly traded company commercializing a dedicated breast CT (computerized tomography) imaging platform, IzoView, for the more-accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.

We seek Safe Harbor.